Evidence-based review of patient-reported outcomes with botulinum toxin type A.
This review systematically examines the effects of botulinum toxin type A (BTX-A) on patient-reported outcomes across disorders using evidence-based criteria. The evidence provided by these studies ranged from randomized, controlled trials to case series. The effects of BTX-A on quality of life or global treatment outcomes were assessed in 48 studies across 16 different conditions. All but 7 of these reported benefits of BTX-A over baseline or the comparator condition (placebo or other treatment). The effects of BTX-A on impairment, activities, or participation were assessed in 46 studies across 17 different conditions. All but 4 reported benefits of BTX-A over baseline or the comparison group. The effects of BTX-A on satisfaction or preference were assessed in 14 studies across 11 different conditions, all of which reported high rates of satisfaction with BTX-A or preference over the comparator. These studies provide evidence that BTX-A exerts meaningful benefits on the quality of life of patients treated with this biologic agent.
Jankovic
Joseph
J
Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA. josephj@bcm.tmc.edu
Esquenazi
Alberto
A
Fehlings
Darcy
D
Freitag
Fred
F
Lang
Amy M
AM
Naumann
Markus
M
D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D009069:Movement Disorders / Q000188:drug therapy* / Q000523:psychology; D017060:Patient Satisfaction; D011788:Quality of Life; D012107:Research Design; D016896:Treatment Outcome
D018726:Anti-Dyskinesia Agents; D019274:Botulinum Toxins, Type A